Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 siRNA conjugate delivery systems.

Literature DB >> 19053311

siRNA conjugate delivery systems.

Ji Hoon Jeong¹, Hyejung Mok, Yu-Kyoung Oh, Tae Gwan Park.

Abstract

Small interfering RNA (siRNA) has been chemically conjugated to a variety of bioactive molecules, lipids, polymers, peptides, and inorganic nanostructured materials to enhance their pharmacokinetic behavior, cellular uptake, target specificity, and safety. To efficiently deliver siRNAs to the target cells and tissues, many different siRNA bioconjugates were synthesized and characterized, and their gene silencing efficiencies were tested in vitro and in vivo. In this review, recent developments of siRNA bioconjugates are summarized.

Entities: Chemical

Mesh：

Substances：
RNA, Small Interfering

Year: 2009 PMID： 19053311 DOI： 10.1021/bc800278e

Source DB: PubMed Journal: Bioconjug Chem ISSN： 1043-1802 Impact factor: 4.774

Keyword Cloud
Cited

78 in total

1. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.

Authors: Vaishali Bagalkot; Xiaohu Gao
Journal: ACS Nano Date: 2011-09-21 Impact factor: 15.881

Review 2. Delivery of siRNA therapeutics: barriers and carriers.

Authors: Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal: AAPS J Date: 2010-06-11 Impact factor: 4.009

Review 3. Clinical developments in nanotechnology for cancer therapy.

Authors: Jeremy D Heidel; Mark E Davis
Journal: Pharm Res Date: 2010-06-12 Impact factor: 4.200

4. Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity.

Authors: Olivia M Merkel; Meredith A Mintzer; Damiano Librizzi; Olga Samsonova; Tanja Dicke; Brian Sproat; Holger Garn; Peter J Barth; Eric E Simanek; Thomas Kissel
Journal: Mol Pharm Date: 2010-08-02 Impact factor: 4.939

siRNA conjugate delivery systems.

1. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.

Review 2. Delivery of siRNA therapeutics: barriers and carriers.

Review 3. Clinical developments in nanotechnology for cancer therapy.

4. Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity.

Review 5. Technologies for controlled, local delivery of siRNA.

Review 6. Delivery materials for siRNA therapeutics.

Review 7. Strategies, design, and chemistry in siRNA delivery systems.

8. Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice.

Review 9. Non-coding RNAs: the new central dogma of cancer biology.

10. Selective inhibition of human brain tumor cells through multifunctional quantum-dot-based siRNA delivery.